The high surface activity, albumin inhibition resistance, and phospholipase resistance of DEPN-8+1.5% Mini-B supports the continuing development of related fully-synthetic exogenous surfactants for treating inflammatory lung injuries such as ALI/ARDS. This evidence concerns the gene ALB and acute respiratory distress syndrome.